Weight-loss drug tied to lower risk of death from COVID, heart disease, all causes-Mary Van Beusekom, MS
The anti-obesity drug semaglutide may lower the risk of death from COVID-19, cardiovascular disease, and all causes, according to a randomized controlled trial published late last week in the Journal of the American College of Cardiology (JACC). Researchers…








